Preclinical drug development must consider the impact on metastasis

Clinical Cancer Research

Volumn 15, Issue 14, 2009, Pages 4529-4530

  Steeg, Patricia S ^a   Anderson, Robin L ^b   Bar Eli, Menashe ^c   Chambers, Ann F ^d   Eccles, Suzanne A ^e   Hunter, Kent ^a   Itoh, Kazuyuki ^f   Kang, Yibin ^g   Matrisian, Lynn M ^h   Sleeman, Jonathan P ⁱ   Theodorescu, Dan ^j   Thompson, Erik W ^b   Welch, Danny R ^k  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^g PRINCETON UNIVERSITY   (United States)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY OF VIRGINIA   (United States)

^k University of Alabama at Birmingham   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; TANESPIMYCIN; VANDETANIB;

BONE METASTASIS; BREAST CANCER; CANCER RESEARCH; CANCER SURVIVAL; CARCINOGENESIS; FIBROSARCOMA; HUMAN; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG METASTASIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 68049083836     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1363     Document Type: Short Survey

References (13)

1. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231
2. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239
3. Man S, Zhang Y, Gao W, Yan L, Ma C. Cyclophosphamide promotes pulmonary metastasis onmouse lung adenocarcinoma. Clin Exp Metastasis 2008;25:855-864
4. Price JT, Quinn JM, Sims NA, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005;65:4929-4938
5. Padera TP, Kuo AH, Hoshida T, et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 2008;7:2272-2279
6. Magenta G, Borenstein X, Rolando R, Jasnis M. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC Cancer 2008;8:47-57.
7. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007;67:2187-2196 (Pubitemid 46424238)
8. Bergamo A, Masi A, Dyson P, Sava G. Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol 2008;33:1281-1289
9. Koto K, Horie N, Kimura S, et al. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett 2009;274:271-278
10. Manni A, Washington S, Craig L, et al. Effects of alpha- difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice. Clin Exp Metastasis 2003;20:321-325 (Pubitemid 36745660)
11. Kishida Y, Yoshikawa H, Myoui A. Parthenolide, a natural inhibitor of nuclear factor-κ β, inhibits lung-colonization of murine osteosarcoma cells. Clin Cancer Res 2007;13:59-67.
12. Titus B, Frierson HF, Jr., Conaway M, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005;65:7320-7327 (Pubitemid 41161264)
13. Biswas S, Guix M, Rinehart C, et al. Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007;117:1305-1313 (Pubitemid 46718418)